Work

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.3001

Authors: G. D. Demetri, J. Desai, J. A. Fletcher, J. A. Morgan, C. D. M. Fletcher, A. Kazanovicz, A. Van Den Abbeele, C. Baum, R. Maki, M. C. Heinrich

Institutions: Brigham and Women's Hospital, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, Pfizer (United States), Dana-Farber Cancer Institute

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603969996

Cites:

Cited by: 107

Related to: 10